Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin plus sitagliptin in treatment-naïve type 2 diabetes mellitus
2014-001049-25Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ertugliflozin, sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2014; status: completed.
02
Drugs
ertugliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001049-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001049-25.